Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The widespread use of SGLT2 inhibitors alongside statins has raised concerns about potential drug interactions. Specifically, findings from a case report suggested a potential link between ...

and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although previous research findings suggest that both medications ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors. SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in ...

To TCTMD, Wiviott said there is a large body of evidence supporting the SGLT2 inhibitor drug class, noting the medications have been a “remarkable advance in diabetes management and the prevention and ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...